Albiruni R. Razak-Abdul

Toronto, ON, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 59 publications

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Immune checkpoint blockade sensitivity is linked to endogenous retroelement transcriptional changes in cancer.

Journal: Cancer immunology research

Published: May 12, 2026

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Phase Ib multicenter study of anti-TIM-3 (S095018/Sym023) in combination with anti-PD-1 (Sym021) in patients with advanced/metastatic recurrent biliary tract cancer.

Journal: Journal for immunotherapy of cancer

Published: February 09, 2026

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Brigimadlin Versus Doxorubicin in Advanced Dedifferentiated Liposarcoma: Efficacy, Safety and Translational Data from Brightline-1, a Randomized Phase 2/3 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: February 04, 2026

Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma.

Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft Tissue Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 22, 2026

Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft-Tissue Sarcoma.

Detecting ctDNA Using Personalized Structural Variants to Forecast Recurrence in Localized Soft-Tissue Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: January 22, 2026

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

Clinical validation of a tissue-agnostic genome-wide methylome enrichment assay to monitor response to pembrolizumab.

Journal: NPJ precision oncology

Published: August 11, 2025

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.

Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study.

Journal: EBioMedicine

Published: July 03, 2025

Elevating Cancer Care Standards Worldwide: An Analysis of Global Initiatives and Progress.

Elevating Cancer Care Standards Worldwide: An Analysis of Global Initiatives and Progress.

Journal: JCO global oncology

Published: December 20, 2024

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Journal: Frontiers in oncology

Published: December 12, 2024

First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.

First-in-Human Study to Evaluate the Safety and Efficacy of Anti-GDF15 Antibody AZD8853 in Patients with Advanced/Metastatic Solid Tumors.

Journal: Cancer research communications

Published: November 15, 2024

ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas.

ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: September 25, 2024

Corrigendum to "Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study" [Eur. J. Cancer, vol. 205 (2024) 114119].

Corrigendum to "Real-word experience of pazopanib and sorafenib in patients with desmoid tumors: A CanSaRCC multi-center study" [Eur. J. Cancer, vol. 205 (2024) 114119].

Journal: European journal of cancer (Oxford, England : 1990)

Published: July 09, 2024

Showing 1-12 of 59

Last Updated: 09/26/2026